| Tasly Technology Center is the scientific research, technology research and product development organization of Tianjin Tasly Holding Group Co., Ltd., and its predecessor was Tianjin Tasly Pharmaceutical Research and Development Center, which was established in 1997. After several years of development and improvement, Tasly Holding Group Technology Center has become a modern enterprise technology center with two major platforms including basic research and industrialization research, as well as related functional management departments, complete functional supporting systems, reasonable structure and advanced facilities. In December 2002, after strict qualification review by the State Economic and Trade Commission and the Enterprise Technology Evaluation Center of the Chinese Academy of Sciences, Tasly Holding Group Technology Center was officially recognized as a national-level enterprise technology center. |
Since the establishment of the Technology Center, Tasly Holding Group Co., Ltd. has continuously increased its capital investment, and scientific research funds have been given special priority guarantees, and the special funds are used in a timely manner. Effectively promote and ensure the stable development of scientific research.
| The technology center is supported by a research and development platform and an industrialization platform. The R & D platform has more than 130 professional and technical personnel including research institutes and post-doctoral workstations, of which 22 are post-doctoral doctors and 38 post-doctoral students. Masters with intermediate and advanced professional titles account for 65% of the total number of the institute. It is not only the basic research and new drug development center of the enterprise, but also the cradle for cultivating senior talents in the pharmaceutical field. It is responsible for the technical development and talent cultivation of the "incubator". It is mainly responsible for the development of new products, pharmacological and efficacy research of marketed products, clinical Basic research such as pharmacological research, extraction and extraction of active ingredients of traditional Chinese medicine, preparation technology and quality standards. |
After years of unremitting efforts, the R & D platform of the Technology Center has initially entered a virtuous circle, formed a new drug development system of "production generation, reserve generation, development generation, and development generation", and has extended to the field of high-tech injectables. At present, there are compound Danshen dripping pills, nourishing serum brain granules, Chaihu dripping pills, Huoxiangzhengqi dripping pills, Tiqing capsules (Temozolomide capsules), Qishenyiqi dripping pills, Jinghua Weikangjiao pills, andrographolide drops Pills, Shuilinjia, Yangxuenao Pills and other products are on the market, and there are more than twenty varieties of new drugs (including traditional Chinese medicine, chemical medicine and biological medicine) in the clinical research stage.
| Industrialization technology platforms include modern Chinese medicine digital extraction pilot test centers, multi-dose pilot test centers, modern pharmaceutical machinery, engineering research centers, and GAP drug source bases. The close integration of industrial research platforms and research and development platforms can promote basic scientific research results as soon as possible. The land is transformed into productivity, realizing production benefits, and further improving product quality and benefits. |
In the construction of the industrialization platform, a series of high-tech such as high-efficiency separation and purification technology in extraction, supercritical extraction technology, automatic control technology in production process, slow and controlled release in preparation, transdermal absorption and targeting technology, etc. Tasly Research Institute continues to deepen scientific research, and strives towards modern Chinese medicine standards, digital extraction technology of traditional Chinese medicine, and modern Chinese medicine preparations. It has made solid and effective work for the establishment of core competitiveness of enterprises, and has taken the lead in proposing Chinese medicine extraction (cGEP) in the country. )standard.
| Tasly Technology Center attaches great importance to the development and patent protection of independent intellectual property products. At the same time as research, it starts to apply for patents. A large number of well-known traditional Chinese medicine prescriptions with value-added potential and years of clinical validation, ancient prescriptions have been re-assigned to the modern Chinese medicine concept after screening prescriptions, pharmacological and pharmacodynamic experiments, and formulation improvements, and have applied for a number of invention patents, basically implementing the key points The product adopts the strategic thinking of patent groups for key protection. By the end of 2006, 235 invention patents had been accepted and 33 invention patents had been authorized. |
In the future, Tasly Technology Center's development vision will highlight modern Chinese medicine, innovative chemical medicine, and biomedical research, covering traditional Chinese medicine, chemical medicine, biological agents, health food and food, and beverages. Through the use of independent research and cooperative research, domestic research and international research, basic research and industrialization research, research of pharmaceutical products and health care products, traditional product development and innovative product development, the research and development strategy combines to form a market with 1 to 5 billion Scientific research system for large product research capabilities.